PTC Therapeutics | PTCT - Cash And Equivalent


PTC Therapeutics reported $1.05B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026